Abstract：Objective To analyze the expression levels of serum microRNA-122 (miR-122) in non-alcoholic fatty liver disease (NAFLD) patients, and its clinical significance. Methods Patients with normal liver, hyperlipidemia, non-alcoholic simply fatty liver(NAFL), non-alcoholic steatohepatitis(NASH)were included in this study. Blood samples of the patients were collected for analysis. Real time quantitative PCR technique was used to measure the expression level of serum miR-122. Results The expression levels of serum miR-122 was 5.94±1.21(2-△△Ct), 5.99±1.03(2-△△Ct), 8.67±0.72(2-△△Ct)and 10.55±0.83(2-△△Ct), respectively. The difference in the expression level between normal liver and hyperlipidemia patients was not statistically significant. Comparing with normal liver and hyperlipidemia patients, miR-122 presented higher expressions in NAFL patients(P<0.05), especially in NASH patients. Conclusion miR-122 plays an important role in NAFLD development and has early diagnostic value for indicating NAFLD. It may also be a potential therapeutic target in NAFLD with significant clinical value.
Brunt E M. Pathology of nonalcoholic fatty liver disease[J].Nat Rev Gastroenterol Hepatol, 2010, 7:195-203.
[7]
Livak K J, Schmittgen T D.Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method[J].Methods, 2001, 25(4):402-408.
[2]
Jopling C. Liver-specific microRNA-122:biogenesis and function[J].RNA Biol, 2012, 9(2):1-6.
[8]
Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116:281-297.
[3]
Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver[J].Nucleic Acids Res, 2008, 36(4):1153-1162.
[9]
Ambros V. The functions of animal microRNAs[J].Nature, 2004, 431(7006):350-355.
[10]
Moore K J, Rayner K J, Suárez Y, et al. microRNAs and cholesterolmetabolism[J]. Trends Endocrinol Metab, 2010, 21(12): 699-706.
[4]
Esau C, Davis S, Murray S F, et al. miR -122 regulation of lipid metabolism revealed by in vivo antisense targeting [J].Cell Metab, 2006, 3(2):87-98.
Gerin I, Clerbaux L A, Haumont O, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation[J]. J Biol Chem, 2010, 285(44):33652-33661.
[7]
Livak K J, Schmittgen T D.Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] Method[J].Methods, 2001, 25(4):402-408.
[13]
Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNA in vivo with 'antagomirs'[J]. Nature, 2005, 438(7068):685-689.
[8]
Bartel D P. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116:281-297.
[9]
Ambros V. The functions of animal microRNAs[J].Nature, 2004, 431(7006):350-355.
[10]
Moore K J, Rayner K J, Suárez Y, et al. microRNAs and cholesterolmetabolism[J]. Trends Endocrinol Metab, 2010, 21(12): 699-706.
[11]
Fernandez-Hernando C, Suarez Y, Rayner K J, et al. MicroRNAs in lipid metabolism[J]. Curr Opin Lipidol, 2011, 22(2): 86-92.
[12]
Gerin I, Clerbaux L A, Haumont O, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation[J]. J Biol Chem, 2010, 285(44):33652-33661.
[13]
Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNA in vivo with 'antagomirs'[J]. Nature, 2005, 438(7068):685-689.
2015, Vol. 26 
